Levetiracetam: A Potential Preventive Treatment for Alzheimer’s Disease

Recent research from Northwestern University has identified a mechanism by which the FDA-approved anti-seizure drug levetiracetam can prevent the formation of toxic amyloid-beta 42 peptides, which are central to the pathology of Alzheimer’s disease. The study, published in *Science Translational Medicine*, reveals that levetiracetam can disrupt the accumulation of these harmful proteins in neurons, potentially offering a new avenue for early intervention in Alzheimer’s.

Common Anti-Seizure Medication Found to Inhibit Formation of Alzheimer’sCommon anti-seizure drug prevents Alzheimer’s plaques from forming

The research team, led by Jeffrey Savas, found that amyloid precursor protein (APP) plays a crucial role in the development of Alzheimer’s. When APP is improperly processed, it leads to the production of amyloid-beta peptides. Levetiracetam binds to the synaptic vesicle protein SV2A, slowing the recycling of synaptic vesicle components. This interaction prolongs APP's presence on the neuron’s surface, diverting it from the pathway that produces amyloid-beta 42. As Savas noted, “In our 30s, 40s and 50s, our brains are generally able to steer proteins away from harmful pathways,” but this ability diminishes with age.

Common Anti-Seizure Medication Found to Inhibit Formation of Alzheimer’sCommon anti-seizure drug prevents Alzheimer’s plaques from forming

To effectively prevent Alzheimer’s symptoms, levetiracetam must be administered “very, very early,” potentially up to 20 years before current diagnostic methods can detect elevated amyloid-beta levels. Savas indicated that high-risk populations, such as individuals with Down syndrome—who are genetically predisposed to early-onset Alzheimer’s—could particularly benefit from this preventive approach. The study also analyzed clinical data from the National Alzheimer’s Coordinating Center, revealing that Alzheimer’s patients taking levetiracetam experienced a significant delay in cognitive decline compared to those on other medications.

Common anti-seizure drug prevents Alzheimer’s plaques from formingCommon Anti-Seizure Medication Found to Inhibit Formation of Alzheimer’s

The findings underscore the importance of early intervention in Alzheimer’s treatment, shifting the focus from reactive therapies targeting existing amyloid plaques to preventive strategies that maintain neuronal health. The research team is also exploring the development of next-generation compounds that could enhance the stability and efficacy of levetiracetam.

Common Anti-Seizure Medication Found to Inhibit Formation of Alzheimer’s

While the study presents promising results, it is essential to acknowledge that levetiracetam is not a perfect solution. The drug's rapid breakdown in the body may limit its effectiveness, and further research is needed to validate these findings in larger, diverse populations.

Common Anti-Seizure Medication Found to Inhibit Formation of Alzheimer’s

• “While many of the Alzheimer’s drugs currently on the market, such as lecanemab and donanemab, are approved to clear existing amyloid plaques, we’ve identified this mechanism that prevents the production of the amyloid-beta 42 peptides and amyloid plaques,” — Jeffrey Savas, Associate Professor of Behavioral Neurology

Common anti-seizure drug prevents Alzheimer’s plaques from forming

• “You couldn’t take this when you already have dementia because the brain has already undergone a number of irreversible changes and a lot of cell death,” — Jeffrey Savas

Common anti-seizure drug prevents Alzheimer’s plaques from forming

• “So conceivably, if you started giving these patients levetiracetam in their teenage years, it could actually have a preventative therapeutic benefit.” — Jeffrey Savas

Common anti-seizure drug prevents Alzheimer’s plaques from forming

The research from Northwestern University highlights levetiracetam's potential as a preventive treatment for Alzheimer’s disease, emphasizing the need for early intervention strategies. As the global population ages, the urgency for effective Alzheimer’s interventions continues to grow, making this discovery a significant step forward in the fight against neurodegenerative diseases.

Common Anti-Seizure Medication Found to Inhibit Formation of Alzheimer’s